SCHEMBL1706510

SCHEMBL1706510

NCC(=O)NCCCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.52
PRMT1 Q99873 1/20 0.50
LMNA P02545 4/20 0.48
KMT2A Q03164 3/20 0.48
THRB P10828 2/20 0.48
BLM P54132 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TSHR P16473 2/20 0.48
GABRR3 A8MPY1 1/20 0.48
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
HDAC3 O15379 1/20 0.48
GABBR2 O75899 1/20 0.48
CYP1A2 P05177 1/20 0.48
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRR1 P24046 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRR2 P28476 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19520656 0.93 PRMT1 (0.59) ATMPRMT1LMNAKMT2ATHRB
SCHEMBL3185096 0.92 ATM (0.46) ATMPRMT1LMNAKMT2ATHRB
SCHEMBL8519057 0.91 PRMT1 (0.63) PRMT1LMNAKMT2ATHRBBLM
SCHEMBL7436387 0.91 PRMT1 (0.63) PRMT1LMNAKMT2ATHRBBLM
SCHEMBL7444117 0.86 PRMT1 (0.52) ATMPRMT1LMNAKMT2ATHRB
SCHEMBL385127 0.86 ECE1 (0.58) LMNAKMT2ATHRBBLMNPSR1
SCHEMBL1769661 0.84 ATM (0.55) ATMPRMT1LMNAKMT2ATHRB
SCHEMBL17177667 0.84 ALDH1A1 (0.41) ATMKMT2ATSHRMEN1ALDH1A1
SCHEMBL9717419 0.83 ECE1 (0.60) ATMPRMT1LMNAKMT2ATSHR
SCHEMBL2806091 0.83 ATM (0.57) ATMPRMT1LMNAKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121577901-A Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof 哈尔滨脉图精准技术有限公司 2026-02-27 CN claimed
CN-121577901-A Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof 哈尔滨脉图精准技术有限公司 2026-02-27 CN disclosed
CN-121577901-A Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof 哈尔滨脉图精准技术有限公司 2026-02-27 CN disclosed
US-20220007684-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-13 US disclosed
US-20220007684-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-13 US disclosed
US-11185594-B2 (Anti-HER2 antibody)-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-11-30 US disclosed
EP-3878287-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Peng, Xianfeng (CN) 2021-09-15 EP disclosed
EP-3878287-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Peng, Xianfeng (CN) 2021-09-15 EP disclosed
CN-111629602-A Application of acylated derivative of amino acid in preparation of animal feed additive 黄华成 2020-09-04 CN disclosed
US-20200276275-A1 Therapies for Obesity, Diabetes and Related Indications PALATIN TECHNOLOGIES INC (US) 2020-09-03 US disclosed
US-20120178701-A1 Melanocortin Receptor-Specific Peptides PALATIN TECHNOLOGIES, INC. (US) 2012-07-12 US disclosed
EP-2440227-A2 MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES Palatin Technologies, Inc. (US) 2012-04-18 EP disclosed
WO-2010144344-A2 MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2010-12-16 WO disclosed
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 US disclosed
EP-0475160-B2 Preparation for drug application in minute droplet form IDEA AG (DE) 2004-07-14 EP disclosed
US-6165500-A Preparation for the application of agents in mini-droplets IDEA AG (DE) 2000-12-26 US disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 EP disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 EP disclosed
US-4900730-A USING CHELATING AGENT AND SOLVENT; HIGH OSMOTIC PRESSURE TOYO JOZO CO., LTD. (JP) 1990-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200276275-A1 Therapies for Obesity, Diabetes and Related Indications MC4R, GLP1R, MC3R ATM 4576/4885PRMT1 3486/4885LMNA 3903/4885
US-11185594-B2 (Anti-HER2 antibody)-drug conjugate ERBB2, EGFR, LANCL2 ATM 1345/4885PRMT1 3228/4885LMNA 139/4885
US-20120178701-A1 Melanocortin Receptor-Specific Peptides MC1R, MC3R, MC5R ATM 4780/4885PRMT1 228/4885LMNA 3579/4885
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA ATM 4581/4885PRMT1 4225/4885LMNA 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.